Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease.
Wayne SilvermanSharon J Krinsky-McHaleWarren B ZigmanNicole Schupfnull nullPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2021)
Significant decline over a 2- to 3-year period for a prospective placebo group of adults with Down syndrome enrolled in clinical prevention trials can only be expected when inclusion is limited to adults older than 45 years of age.